BioSpace News Archive

DBV Technologies, located just outside Paris, announced it is cutting jobs while it awaits news from the U.S. Food and Drug Administration (FDA) about its application for Viaskin Peanut.

Salt water gargle is a time-tested way to alleviate sore-throat pain. It can help clear stuffy sinuses. But, is it effective against the symptoms of COVID-19?

Clinical-stage biotechnology company BioNTech announced a private investment of $250 million today, led by Temasek and other investors.

San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.

Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $390 per vial, which for most patients receiving a 5-day treatment using six vials, would come to $2,340 per patient.

The U.S. Food and Drug Administration (FDA) issued Heron Therapeutics a Complete Response Letter (CRL) for its New Drug Application (NDA) for HTX-011 for the management of postoperative pain.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.

Specifically, the report indicated that biotechnology companies drove the healthcare industry to make up almost two-thirds of IPO activity in the second quarter of 2020.

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management solutions announced that a global pharma giant based in Japan, chose ValGenesis’s cloud-based, 100% paperless Validation Lifecycle Management System, to digitalize their validation lifecycle process first in Europe and subsequently in facilities across the globe.

- Updated data will be presented in an oral presentation on the efficacy and safety of AAV gene therapy FL180a in the B-AMAZE study in severe haemophilia B patients - - Additional data will be presented in 5 poster presentations -